Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors (Q45394600)

14 December 2017

Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors (English)

1 reference

14 December 2017

1 reference

1 reference

Newcastle disease virus

object named as

Newcastle disease virus

1 reference

B Yaacov

1

1 reference

14 December 2017

E Eliahoo

2

1 reference

14 December 2017

I Lazar

3

1 reference

14 December 2017

M Ben-Shlomo

4

1 reference

14 December 2017

I Greenbaum

5

1 reference

14 December 2017

A Panet

6

1 reference

14 December 2017

Z Zakay-Rones

7

1 reference

14 December 2017

6 June 2008

1 reference

14 December 2017

1 reference

14 December 2017

15

1 reference

14 December 2017

12

1 reference

14 December 2017

795-807

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2008.31

14 December 2017

0 references

cites work

Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

Emerging therapies in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

High dose radiation therapy and chemotherapy as induction treatment for stage III nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Newcastle disease virus (NDV): brief history of its oncolytic strains

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Apoptosis: mechanisms and relevance in cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Apoptosis is promoted by the dsRNA-activated factor (DRAF1) during viral infection independent of the action of interferon or p53.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Characteristics of a human diploid cell designated MRC-5.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

PAX6 suppresses growth of human glioblastoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Flow cytometry in analysis of cell cycle and apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Etoposide: four decades of development of a topoisomerase II inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Expression of an anti apoptotic recombinant short peptide in mammalian cells.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Contribution of the length of the HN protein and the sequence of the F protein cleavage site to Newcastle disease virus pathogenicity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Newcastle disease virus V protein is a determinant of host range restriction

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

An optimized clinical regimen for the oncolytic virus PV701.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

The lectin neuraminidase inhibition test: a new method for the detection of antibodies to neuraminidase

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Isolation of factor Xa from chick embryo as the amniotic endoprotease responsible for paramyxovirus activation

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.31

7 January 2021

Identifiers

DOI

10.1038/CGT.2008.31

1 reference

Dimensions Publication ID

14 December 2017

0 references

1 reference